rdf:type |
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0040207,
umls-concept:C0087111,
umls-concept:C0288672,
umls-concept:C0521115,
umls-concept:C0522523,
umls-concept:C0919737,
umls-concept:C1522318,
umls-concept:C1948041,
umls-concept:C1979963,
umls-concept:C2003903,
umls-concept:C2348480
|
pubmed:issue |
3
|
pubmed:dateCreated |
2000-9-27
|
pubmed:abstractText |
We examined the ex vivo platelet aggregation profiles of patients who underwent percutaneous coronary intervention and received either abciximab, ticlopidine, or both agents.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
AIM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0002-8703
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
140
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
492-501
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:10966553-Aged,
pubmed-meshheading:10966553-Angioplasty, Balloon, Coronary,
pubmed-meshheading:10966553-Antibodies, Monoclonal,
pubmed-meshheading:10966553-Coronary Thrombosis,
pubmed-meshheading:10966553-Drug Therapy, Combination,
pubmed-meshheading:10966553-Female,
pubmed-meshheading:10966553-Humans,
pubmed-meshheading:10966553-Immunoglobulin Fab Fragments,
pubmed-meshheading:10966553-Male,
pubmed-meshheading:10966553-Middle Aged,
pubmed-meshheading:10966553-Platelet Aggregation Inhibitors,
pubmed-meshheading:10966553-Platelet Function Tests,
pubmed-meshheading:10966553-Postoperative Complications,
pubmed-meshheading:10966553-Prospective Studies,
pubmed-meshheading:10966553-Ticlopidine
|
pubmed:year |
2000
|
pubmed:articleTitle |
Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions.
|
pubmed:affiliation |
Baylor College of Medicine and the Methodist Hospital, Houston, TX, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|